NCT04144049

A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 176 (actual)
• Sponsor: Medy-Tox · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is a randomized, double-blind, placebo-controlled, dose-ranging, parallel, multi-center, phase II study to evaluate the efficacy and safety of MT921 in subjects with moderate to severe submental fat.

Conditions

• Submental Fat

Interventions

Type	Name	Description
DRUG	MT921	Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
DRUG	Placebo	Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.

Timeline

• Start date: 2019-09-10
• Primary completion: 2020-03-10
• Completion: 2020-04-23
• First posted: 2019-10-30
• Last updated: 2020-07-29

Locations

1 site across 1 country: South Korea